Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
AuthorsWardley, Andrew M
AffiliationChristie Hospital, Manchester, England. email@example.com
MetadataShow full item record
AbstractIn recent years, several major trials have studied aromatase inhibitors (AIs)/inactivators as adjuvant therapy for postmenopausal women with early-stage breast cancer. The AIs have demonstrated improved efficacy compared with 5 years of tamoxifen when used as initial therapy or when used sequentially after 2-3 years. They also improve outcomes when used after 5 years of adjuvant tamoxifen in this patient population. In all cases, AIs improve disease-free survival compared with the standard 5 years of adjuvant tamoxifen, leading to a reassessment of the optimal adjuvant endocrine therapy for postmenopausal patients with breast cancer. The American Society of Clinical Oncology now recommends the inclusion of an AI into the adjuvant regimen at some point for most postmenopausal patients with hormone receptor-positive early-stage breast cancer. However, the optimal duration of AI therapy and the comparative efficacy and safety of the alternative strategies for their incorporation remain matters of debate. In addition, the long-term impact of AIs on other organs, such as the bone and cardiovascular systems, is not completely understood, and longer follow-up of patients from these original trials as well as carefully planned future trials with appropriate substudies are essential to determine the optimal endocrine treatment strategy.
CitationEmerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. 2006, 6 Suppl 2:S45-50 Clin. Breast Cancer
JournalClinical Breast Cancer
- Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
- Authors: Jahanzeb M
- Issue date: 2007 Aug
- Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
- Authors: Carpenter R
- Issue date: 2008 Jul
- Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
- Authors: Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H, Austrian Breast and Colorectal Cancer Study Group.
- Issue date: 2007 Dec 19
- Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
- Authors: Carlson RW, Henderson IC
- Issue date: 2003
- Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
- Authors: Goss PE
- Issue date: 2006 Apr